Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
ER-positive breast cancer patients do not usually respond to immunotherapy. In this phase II clinical trial, the authors report the safety and efficacy of combining vorinostat and pembrolizumab with tamoxifen in ER-positive breast cancers and provide evidence that T-cell exhaustion may serve as a po...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2020
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/64f0fec706954f5c93dba4c047a3944a |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|